Here are some highlights from this past week's earnings coverage from BloggingStocks:

• American Capital Agency Corp. (NASDAQ: AGNC) earnings prospects earned it an analyst's upgrade.
• Broadpoint Securities Group Inc. (NASDAQ: BPSG) earnings prospects improved with recent acquisitions.
• Clorox Co. (NYSE: CLX) was upgraded on the belief that its fiscal year outlook is too conservative.
• Deutsche Bank (NYSE: DB) earnings prospects resulted in an upgrade from JPMorgan.
• Lululemon Athletica Inc. (NASDAQ: LULU) Q1 profit and same-store sales fell and it offered a weak outlook.
• Movado Group Inc. (NYSE: MOV) bested Q1 expectations and forecast a considerable profit for the full year.

Even as the holiday season ramps up and the calendar quarter begins to wind down, earnings reports continue to dribble in. Among the companies scheduled to release quarterly results this coming week, analysts surveyed by Thomson Reuters are expecting BWAY Holding Co. (NYSE: BWY), Powell Industries Inc. (NASDAQ: POWL), and Esterline Technologies Corp. (NYSE: ESL) to be among the biggest earnings gainers.

Atlanta-based packaging and container producer BWAY is expected to report fiscal fourth-quarter profits that are 65.6% higher than in the same period of last year, or $0.32 per share on revenues of $265.2 million (+4.9%). BWAY topped estimates in the previous two quarters -- by 44.9% in the third quarter. Those results sent shares to a new 52-week high. But shares have fallen 62.7% in the past three months, and they are now trading near a multiyear low of $4.11 per share.

Houston-based energy equipment maker Powell is expected to report fiscal fourth-quarter profits that are 62.7% higher than a year ago, or $0.59 per share. Revenues are forecast to be 14.2% higher, or $171.8 million. Powell beat expectations in the past three quarters -- by 20.2% in the third quarter. The share price has fallen 47.7% in the past three months, and the consensus recommendation is to buy POWL.

Jim Cramer reviewed a last Fallen Angel on CNBC's MAD MONEY tonight: Quest Diagnostics (NYSE:DGX). He owns it in his trust, for disclosure. He said that Quest losing Oxford's business (UnitedHealth Group NYSE:UNH) took the stock down under $49. The company had already announced the news a month earlier. He isn't minimizing the business loss, or so he says, because it was $400 million of their $6 billion in total business. The company beat last week by $0.05 on EPS, but lowered guidance. He said it traded up $1.00 because the street is assuming it is conservative. He thinks it could earn $3.10 and they are low-balling estimates at $2.95. It closed at $52.25 and is now up at $52.90 in after-hours. J.P.Morgan just raised it and a broker luncheon on it last week was over-attended.

Cramer interviewed the CEO of Jones Soda (NASDAQ:JSDA), Peter van Stolk, before closing down MAD MONEY until tomorrow. It lost Target business, but he said that is only 2% of their business. The company doesn't use high-fructose corn syrup, they use cane sugar. Cramer doesn't think it has finished rising. The company won't be announcing any new product data until the first week of March. Cramer said it was up $1.00, but he said let it pull-back and then you can buy it since it was up so much today. This after-hours pop before it came in is another yearly high, and the company had a $376 million market cap as of the close. This stock, if it meets the $0.14 estimate in 2007 without beating estimates, then it now trades at 100-times December 2007 fiscal EPS projections. He's been behind this one before (back on December 21 he called the next Hansen Natural [NASDAQ:HANS]), on more than one occasion.

Jon Ogg is a partner in 24/7 Wall St., LLC; he does not own securities in the companies he covers.